1 / 30

Heart Failure

Heart Failure. 2006 CCS Guidelines & 2012/13 update Michelle Gibson http:// www.ccsguidelineprograms.ca / index.php?option = com_content&view = article&id =185&Itemid=107. My Advice. Read the 2006 guidelines if you haven’t Then, skim the 2012 update Acute Chronic

belden
Download Presentation

Heart Failure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Heart Failure 2006 CCS Guidelines & 2012/13 update Michelle Gibson http://www.ccsguidelineprograms.ca/index.php?option=com_content&view=article&id=185&Itemid=107

  2. My Advice • Read the 2006 guidelines if you haven’t • Then, skim the 2012 update • Acute • Chronic • Updates 2007-2011 – interesting, not essential • 2013 – rehab and revascularization

  3. Chronic HF

  4. Source: Canadian Journal of Cardiology 2013; 29:168-181 (DOI:10.1016/j.cjca.2012.10.007 )

  5. Chronic HF • Diagnosis is clinical, but… • Triad of edema, fatigue and dyspnea is not sensitive or specific • Atypical presentations in women, elderly, obese patients

  6. CHF - diagnosis • H & P, BNP? • 12 lead ECG – rhythm, rate, QRS, etc. • Echo – to assess systolic and diastolic function, valves, LV, etc. • Angiography if angina present, if candidate for interventions • NYHA

  7. CHF – preserved EF • 50% of patients in HF clinics • More prevalent in elderly, women, HTN • Less mortality (still high), but equal morbidity • This is easy: • No evidence for management. • Control risk factors, use diuretics judiciously, control rate (b-blockers and CCBs)

  8. CHF – Non-pharm • Regular exercise – stable sxwith impaired EF • 3-5 times/week, 30-45 mins • Aerobic and resistance – moderate intensity • May need graded stress test first • Refer to cardiac rehab!

  9. CHF – non-pharm • Sodium restriction! • 2-3 g of salt/day (less if severe) • Daily morning weights • Fluid restriction to 1.5 to 2 L/d ***in patients with fluid issues, not managed by diuretics • Read – not all patients! • Refer to CHF program if available

  10. ACE inhibitor • For everyone post MI • For everyone with EF <35% (even if asymptomatic); <40% if symptomatic

  11. ARB • If intolerant to ACE • Added to ACE with NYHA II-IV and EF <40% “if deemed at increased risk” • (NB – be CAREFUL!) • Consider if b-blockers are contraindicated or not tolerated

  12. MRA • Mineralocorticoid receptor antagonists: • Spironolactone • Eplerenone • Complex recommendations - HUH? • >55 yrs, EF < 30% (or <35% with QRS > 130), and recent CV admission OR ^NP –(epl.) • Post MI, EF <30% and HF; or EF <30% with DM. (epl.) • *EF < 30%, NYHA IIIb-IV; otherwise optimized

  13. Practical tips • Try to back off on diuretics when starting other meds • R/A need for vasodilators when stable • OK for Cr increase up to 30% • Check electrolytes (Na/K) • Keep K+ > 4 mmol/L • ACE/ARB combo – use with caution!

  14. CHF – b blockers • All with EF <40% • Class IV, though – stabilize before adding BB • Start low, titrate up to target or max tolerated dose • Don’t start if symptomatic hypotension that you can’t fix; if bad RAD, symptomatic brady, AV block. • Stable COPD is OK.

  15. Practical tip • May need to wait 6 -12 months before improvement after b-blocker initiated • Try not to stop abruptly – try to reduce dose, back off on other meds if possible

  16. Diuretics • Most patients need loop diuretic (no kidding) • Use lowest dose possible – can often decrease • May need thiazide or low-dose metolazone • Monitor lytes, renal function, BP carefully

  17. Digoxin • In NSR, with mod to severe sx despite optimal therapy • In A-fib – to rate control if b-blockers not enough, or contraindicated

  18. ISDN and hydralazine • Use in addition to standard therapy in black patients • Consider in other patients unable to tolerate ANCE or ARB

  19. Omega-3 • 1gm daily – consider – in HF and reduced EF

  20. Platelet inhibition & anticoag • ASA – 81mg to 325mg – ONLY if needed otherwise for 2nd prevention • Recommend against routine use of anticoag in NSR patients • Consider anticoag if intra-cardiac thrombus or after large anterior MI

  21. Miscellaneous • Cardiac resynchronization – check the list.

  22. Avoid!

  23. Avoid • NSAIDs • Cox II inhibitors • Glitazones • Negative inotrope CCBs and anti-arrhythmics

  24. Quiz • Which drug classes have been shown to decrease mortality? • Morbidity? • Neither?

  25. Acute HF • After your H & P, normally need: • Labs, ECG, CXR, Echo • Use a scoring system:

  26. Acute HF • Role for BNP: • When the clinical diagnosis is uncertain • Key point in diagnosis: • “Evaluate the clinical constellation of findings .. vs. focus on individual findings, symptoms, or investigation”

  27. AHF - treatment • O2 for hypoxemia; to keep sats >90% • No role for routine CPAP/BiPAP • IV diuretics for patients with congestion • Furosemide bid or continuous infusion • Vasodilators (but keep SBP>100), for relief of dyspnea in hemodynamically stable patients • e.g. nitroglycerine

  28. AHF – treatment • Continue b-blockers unless hypotensive or bradycardic

  29. My thoughts • Know the difference between normal EF and decreased EF • Know non-pharmacological mgt • Know drugs- morbidity & mortality.

More Related